Design and validation of a conformation sensitive capillary electrophoresis-based mutation scanning system and automated data analysis of the more than 15 kbp-spanning coding sequence of the SACS gene. by Vermeer, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/80180
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Technical Advance
Design and Validation of a Conformation Sensitive
Capillary Electrophoresis-Based Mutation Scanning
System and Automated Data Analysis of the More
than 15 kbp-Spanning Coding Sequence of the
SACS Gene
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Hans Scheffer*
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the Nijmegen Centre for Molecular Life Sciences,† Radboud
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In this study, we developed and analytically validated
a fully automated, robust confirmation sensitive cap-
illary electrophoresis (CSCE) method to perform mu-
tation scanning of the large SACS gene. This method
facilitates a rapid and cost-effective molecular diagno-
sis of autosomal recessive spastic ataxia of Charle-
voix-Saguenay. Critical issues addressed during the
development of the CSCE system included the posi-
tion of a DNA variant relative to the primers and the
CG-content of the amplicons. The validation was per-
formed in two phases; a retrospective analysis of 32
samples containing 41 different known DNA variants
and a prospective analysis of 20 samples of patients
clinically suspected of having autosomal recessive
spastic ataxia of Charlevoix-Saguenay. These 20 sam-
ples appeared to contain 73 DNA variants. In total, in
32 out of the 45 amplicons, a DNA variant was
present, which allowed verification of the detection
capacity during the validation process. After optimi-
zation of the original design, the overall analytical
sensitivity of CSCE for the SACS gene was 100%, and
the analytical specificity of CSCE was 99.8%. In con-
clusion, CSCE is a robust technique with a high ana-
lytical sensitivity and specificity, and it can readily be
used for mutation scanning of the large SACS gene.
Furthermore this technique is less time-consuming
and less expensive, as compared with standard auto-
mated sequencing. (J Mol Diagn 2009, 11:514–523; DOI:
10.2353/jmoldx.2009.090059)
Autosomal recessive spastic ataxia of Charlevoix-Saguenay
(ARSACS) belongs to a heterogeneous group of neuro-
degenerative disorders characterized by ataxia, mostly
due to progressive degeneration of the cerebellum and
associated structures. The clinical phenotype of these
disorders is broad and quite variable. Clinically it can
sometimes be hard to distinguish the different types of
cerebellar ataxia. Molecular diagnosis can be ex-
tremely helpful to differentiate between the different
forms of ataxia.
Using DNA analysis to confirm the clinical diagnosis of
ARSACS (MIM 270550) has been hampered in the ma-
jority of patients worldwide due to the lack of an efficient
and cost-effective mutation scanning system for the
SACS gene. The large size of the total coding sequence
of this gene has precluded sequencing of the total cod-
ing sequence of the SACS gene as a routine diagnostic
service. Since automated sequencing of this large gene
is labor-intensive, costly, and time-consuming, we devel-
oped mutation screening by designing a heteroduplex
analysis system using conformation-sensitive capillary
electrophoresis (CSCE), which is a simple, rapid, reliable,
and sensitive technique enabling a high sample through-
put1 and automated DNA variant identification. We have
chosen this method because it can be used for the analysis
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of larger fragment sizes (up to 500 bp), it has a higher
sensitivity, and it can easily be implemented in existing
automated sequencer infrastructure. DNA analysis there-
fore becomes more reliable, more robust, less expensive,
and has a higher throughput, in comparison with estab-
lished techniques such as single-strand confirmation poly-
morphism, denaturing gradient gel electrophoresis, and de-
naturing high performance liquid chromatography.2
The SACS gene involved in ARSACS is located on chro-
mosome 13q12.12 and encodes the large protein sacsin.3
The gene consists of at least 11 exons, of which 9 contain
coding sequences, spanning 13,737 bp and 4579 amino
acids (NM_014363.4). To date, apart from the twomutations
originally identified in the ARSACS patients from Que´bec,
30 different additional mutations, including nonsense, mis-
sense, small deletions and insertions, have been identified
in ARSACS patients from different countries. These muta-
tions occur throughout the entire gene.
Not all types of mutations will be detected by sequenc-
ing or alternative subtle mutation scanning techniques
such as CSCE. For instance, recently a Belgian ARSACS
patient has been described with a 1.5-Mb deletion on
chromosome 13q12.12 encompassing the SACS gene
and a missense mutation on the other allele.4 This under-
lines that additional mutation detection techniques will
still be needed.
Here, we report the development of a fully automated,
robust CSCE method to perform mutation scanning of the
large SACS gene, facilitating a rapid and cost-effective
molecular diagnosis of ARSACS patients. Since the co-
hort of Dutch ARSACS patients had been thoroughly
analyzed for SACS mutations by automated direct se-
quencing, a good starting point for the analytical valida-
tion of the CSCE mutation scanning including automated
heteroduplex pattern analysis had already been created.
A technical validation of the CSCE technique in general
has been performed as an interlaboratory collaborative
project previously5; details will be published elsewhere.
The analytical validation of CSCE specifically for the
SACS gene presented here has been performed in two
phases: a retrospective analysis of samples containing
known DNA variants in the SACS gene and a prospective
analysis of samples of patients for whom SACS mutation
analysis was requested by a physician. Issues ad-
dressed during the development of a CSCE system for
mutation scanning are discussed and illustrated with ex-
amples. These include the position of a DNA variant
relative to the primers, and the CG content of the ampli-
cons. Finally an overview of all novel SACS mutations and
single nucleotide polymorphisms (SNPs) identified in a
cohort of 76 patients for whom SACS mutation analysis
was requested is presented (Tables 15 and 2).
Materials and Methods
Patients
Peripheral blood was collected using EDTA as an anti-
coagulant from index patients with recessive cerebellar
ataxia. Automated genomic DNA extraction was per-
formed using a Tecan Freedom EVO 150 workstation
combined with a Chemagic Magnetic Separation Module
1 from Chemagen. The concentration of DNA samples
were standardized at 100 ng/l. For the validation, in total
52 DNA samples of patients were used who either have
ARSACS confirmed at the DNA level or known variants in
the SACS gene (retrospective phase), or who were sus-
pected of having ARSACS (prospective phase). The re-
maining 24 patients for whom mutation data were avail-
able have not been included in the validation study to
avoid redundancy, ie, no additional fragments would
have been validated by their inclusion. To facilitate the
detection of homozygous mutations, before CSCE, the
PCR product of a patient was mixed with the PCR product
of a mutation-negative reference sample to allow the
formation of heteroduplex bands. For this purpose, we
used two different reference samples (V3 and V4). These
samples were sequenced in advance to identify the DNA
variants present in the different amplicons of the SACS
gene. Informed consent was obtained from all patients
included in this study.
PCR Amplification
We designed 45 overlapping PCR primer pairs for the
nine coding exons (Table 3), including the gigantic exon
9 described previously3 and the flanking intronic se-
quences of the SACS gene (GenBank reference se-
quence accession number NM_014363.4, NCBI). All for-
ward primers (FPs) and reverse primers (RPs) contain
next to the specific primer an universal primer tag
(M13), (FP) 5-TGTAAAACGACGGCCAGT-3 and (RP)
5-CAGGAAACAGCTATGACC-3. The primer sequences,
positions and size of each amplicon are listed in Table 3.
The DNA-amplification mix included (per amplicon per
sample) 1.0 l genomic DNA, 0.36 l (8.33 mmol/L)
dNTPs, 1.44 l MgCl2 (50 mmol/L, AB), 1.80 l 10 PCR
Gold Buffer (AB), 0.14 TaqDNA polymerase Gold (5
U/l), 6.26 l distilled H2O (mQ), and 7 l FP and RP (10
pmol/l) from a mix of 0.16 l FP and RP per 1 l mQ. The
reaction volume per sample was 18 l. The samples were
PCR amplified using the following PCR program on a
Perkin-Elmer (ABI) Geneamp 9700: an initial denaturation
at 94°C for 5 minutes, followed by 35 cycles of denatur-
ation at 94°C for 30 seconds, annealing at 58°C for 30
seconds, and elongation at 72°C for 1 minute, with a final
step at 72°C for 7 minutes, after which the samples are
cooled down to 10°C. Before CSCE, 5 l of each PCR-
product with 7 l Loading Orange G was run on a 1%
agarose gel with a 100-bp marker for comparison. Next,
all PCR-products (13 l) were purified using a Multi-
screen PCR96 filter plate (Millipore, Tullagreen, Carrigt-
wohill, County Cork, UK).
For fragment 2 (exon 2) a different PCR program and
amplification mix is used; 0.5 l (8.33 mmol/L) dNTPs,
3.0 l MgCl2, 3.0 l PCR Gold Buffer, 7.5 l Betaine,
0.2 l Tag DNA polymerase Gold, 13.8 mQ, 1 l FP and
RP (10 pmol/l) with 1.0 l genomic DNA in a total
reaction volume of 30 l per sample. The PCR program
is as follows: initial denaturation at 94°C for 5 minutes,
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then 38 cycles of denaturation at 98°C for 5 seconds,
annealing at 68°C for 30 seconds, and elongation at
72°C for 50 seconds, with the final step at 72°C for 7
minutes, after which the samples are cooled down
to 10°C.
CSCE
During CSCE, the target gene is PCR-amplified and PCR
products are denatured and re-annealed slowly, so that
four different double stranded (ds) DNA molecules, ie,
two homoduplexes and two heteroduplexes, can be
formed if a heterozygous mutation is present. To identify
conformational changes resulting in a mobility shift, the
re-annealed PCR products can be analyzed using any
capillary DNA sequencer, and by using non-denaturing
conditions, ie, an ABI 3730 sequencer with conformation
analysis polymer-containing capillaries. The re-annealed
PCR products can be detected by using a four-dye filter
set, and fluorescently labeled primers. The presence of
many SNPs in the gene of interest will lead to the identi-
fication of these as DNA variants in several samples,
depending on their allele frequency. These DNA variants
will all have to be subsequently analyzed by automated
sequencing. CSCE therefore is most suited for genes
containing just a limited number of (common) SNPs. The
peak patterns are analyzed automatically by specially
designed software (BioNumerics, Applied Maths, St-Mar-
tens-Latem, Belgium).
CSCE Conditions
Before CSCE, 5 l purified PCR-product was mixed with
2 l PCR-product of a mutation-negative reference sam-
ple (V3). For the amplicons 7 and 10 of the SACS gene a
different reference sample (V4) was used since the V3
sample was heterozygous for common SNPs in these
amplicons. The labeling-PCR mix contained 0.2 l 6-car-
boxyfluorescein-labeled FP, 0.2 l reverse M13 primer,
0.5 l dNTPs (8.33 mmol/L), 1.5 l MgCl2 (50 mmol/L,
AB), 2.5 l 10 PCR Gold Buffer (Applied Biosystems,
Inc, Foster City, CA), 0.2 l TaqDNA polymerase Gold (5
U/l), and 17.9 l mQ. Of this mix 18 l was used per
sample for the labeling-PCR. The following PCR program
was used for the labeling-PCR: an initial denaturation at
94°C for 5 minutes, followed by 10 cycles of denaturation
at 94°C for 30 seconds, annealing at 58°C for 30 sec-
onds, and elongation for 1 minute at 72°C, with a final
Table 1. Known and Novel Mutations Detected by CSCE and Sequencing
Exon Amplicon Variant
Predicted protein
change
Predicted
consequence
Mutation
type Position
Number of
occurrences
6 6 c. 502GT p. Asp168Tyr Amino acid
substitution
Missense 174/390 2
7 8 c. 961CT p.Arg321X Premature termination
codon
Nonsense 226/466 2
9//10 c. 1475GA p.Trp492X Premature termination
codon
Nonsense 448/484//84/449 1
8 12 c. 2094-2AG Aberrant splicing Splice site 92/2 99 1
c. 2182CT p.Arg728X Premature termination
codon
Nonsense 182/299 2
c. 21851del Aberrant splicing Splice site 186/299 2
9 18* c. 4108CT p.Gln1370X Premature termination
codon
Nonsense 365/464
21 c. 4957GT p.Glu1653X Premature termination
codon
Nonsense 100/484 2
c. 5125CT p.Gln1709X Premature termination
codon
Nonsense 268/484 1
c. 5143AT p.Lys1715X Premature termination
codon
Nonsense 286/484 1
23/24 c. 6000_6004del p.Arg2002fs Premature termination
codon
Deletion 468–472/492//100–104/466 1
26* c. 6835dupA p.Glu2280fs Premature termination
codon
Insertion 241–242/463
27* c. 7250_7254del p.Thr2417fs Premature termination
codon
Deletion 318–322/486
30 c. 8401-8403del p.Gln2801del Single amino acid
deletion
In frame
deletion
319–321/489 2
34/35 c. 9911_9912del p.Leu3304fs Premature
termination codon
Deletion 413–414/481//49–50/474 1
36 c. 10442TC p.Leu3481Pro Amino acid
substitution
Missense 260/496 1
37 c. 10906CT p.Arg3636X Premature termination
codon
Nonsense 393/464 1
41 c. 12160CT p.Gln4054X Premature termination
codon
Nonsense 195/485 11
43 c. 12992GA p.Arg4331Gln Amino acid
substitution
Missense 351/486 1
*Known Italian mutations (Grieco et al5).
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step at 72°C for 7 minutes after which the samples are
cooled down to 10°C. After the labeling PCR, the prod-
ucts (25 l) are again purified as described before. Per
sample 1 l pooled PCR product, was mixed with 9 l
standard LIZ-500 (Applied Biosystems)/mQ-mix (in
proportion 0.2 l Liz to 8.8 l mQ), before running the
actual CSCE. The analysis was performed using an ABI
3730 automated sequencer (Applied Biosystems) us-
ing capillaries containing conformation analysis poly-
mer. Results were analyzed using BioNumerics 5.0
(Applied Maths NV, Sint-Martens-Latem, Belgium) soft-
ware. We choose to run four patient samples in a single
CSCE run.
Automated CSCE Pattern Analysis
To automatically analyze the CSCE electropherograms of
the different amplicons of the SACS gene by the data
analysis software program Bionumerics an optimized set
of parameters (quantified characteristics of the shapes of
the electropherogram) has been used. The parameters
include (1) the relative position of the peak within the
electropherogram, and (2) the signal-width as a percent-
age of the run length, and (3) the left and right control
range, ie, the area flanking the main peak signal in which
the algorithm will search for additional peaks. To further
characterize the shape of the peaks (curves), the algo-
rithm calculates five different pattern-matching parame-
ters, ie, SRMS, MAX, SECPK, DFH3, and DFH4. SRMS
stands for single-sided root mean square value, and is
calculated from the highest 50% of square differences
between the curves compared. MAX determines the
highest difference between any corresponding values on
the two curves. SECPK calculates the proportion of a
secondary peak relative to the primary peak of the curve.
DFH3 is a parameter for the difference in H3 parameters
between the signal and the reference (H3 is a measure of
the deviation from symmetry, compared with a Gaussian
curve derived from reference samples without DNA vari-
ants), whereas DFH4 determines the deviation from a
theoretical Gaussian curve. The parameters SRMS and
MAX take into account any difference between the
curves, the parameters SECPK, DFH3, and DFH4 each
apply to a specific component of the curve. For a correct
match interpretation a peak height has to be above 1000
and below 32000 relative fluorescence units. Peak
heights outside this range will be regarded as failures by
the BioNumerics program.
Table 2. Polymorphisms Detected by CSCE and Sequencing
Exon Amplicon Variant
Predicted protein
change Predicted consequence
Mutation
type Position
Number of
occurrences
1 1 c.1-219 AG 145/585 10
c.1-13AG 351/585 18
2 2 c.1716CT 3
c.17124GA 1
3 3 c.172-129AG 1/343 1
c.25928AG 245/343 1
5 5 c.346-143GA 79/391 4
7 7 c.696TA p.Asn23 2Lys Amino acid substitution Missense 189/327 13
8 c.909AG p.Ala3 03Ala Amino acid substitution Missense 174/466 9
c.973GA p.Gly325Arg Amino acid substitution Missense 238/466 1
10 c.1656AG p.Leu552Leu Amino acid substitution Missense 265/449 14
11 c.1846GC p.Ala6 16Pro Amino acid substitution Missense 385/488 1
c.2080GA p.Ala6 94Thr Amino acid substitution Missense 151/488 7
9 13/14 c.2472GA p.Ser 824Ser Amino acid substitution Missense 374/459//76/475 1
15 c.2983GT p.Val995Phe Amino acid substitution Missense 252/494 1
c.2988AG p.Leu996Leu No change Missense 257/494 2
19 c.4188CT p.His1396His No change Missense 86/498 2
c.4466AG p.Asn14 89Ser Amino acid substitution Missense 364/498 3
24 c.6195TC p.Ile 2065Ile No change Missense 294/466 40
c.6267GA p.Ser 2089Ser No change Missense 366/466 2
26 c.6781CA p.Leu2261Ile Amino acid substitution Missense 187/463 1
c.6946AG* p.Thr 2316Ala Amino acid substitution Missense 1
27 c.7140TA p.Asn24 80Lys Amino acid substitution Missense 208/486 1
c.7149CT p.Arg2383Arg No change Missense 217/486 1
28 c.7539CT p.Val2513Val No change Missense 243/498 1
31/32 c.8853TC p.Val2951Val No change Missense 404/491//52/494 44
34 c.9801AG* p.Thr 3267Thr No change Missense 1
c.9846AG p.Pro3282Pro No change Missense 348/481 1
35 c.9981TC p.Ala3327Ala No change Missense 119/473 87
c.10106TC p.Val3369Ala Amino acid substitution Missense 244/473 43
36 c.10338GA p.Gln344 6Gln No change Missense 156/494 4
38 c.11032CG p.Pro36 78Ala Amino acid substitution Missense 153/499 5
41 c.12304TC p.Leu4102Leu No change Missense 339/485 27
43 c.12813TC p.Pro42 71Pro No change Missense 121/486 1
45 c.13522AC p.Lys4508Gln Amino acid substitution Missense 183/483 1
c.13717AC p.Asn45 73His Amino acid substitution Missense 377/483 1
*SNP not validated.
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Sequence Analysis
In this validation study, all samples have been analyzed
in parallel by CSCE and by automated sequencing. Se-
quence reactions were run on an ABI 3730 automated
sequencer and analyzed with a combined software pro-
gram: Phred, Phrap, and Polyphred (University of Wash-
ington). In affected siblings or relatives of patients with
one homozygous or two compound heterozygous muta-
tions in the SACS gene, the presence of the mutations
was identified or excluded using direct sequencing. Due
to the occurrence of two relatively frequent polymor-
phisms in amplicon 35, which are heterozygous in both
reference samples V3 and V4, direct sequencing is pre-
ferred over CSCE for this amplicon, since aberrant het-
eroduplex patterns will occur in the majority of cases. As
the PCR-mix and program conditions for exon 2 of the
SACS gene differ substantially from standard conditions,
CSCE conditions for this specific exon have not been
developed.
Results
Design
Primers were designed (a) to allow for an identical an-
nealing temperature for all 45 amplicons, except for am-
plicon 2 (exon 2) for which a different annealing temper-
ature is used because of the high CG-content of this
fragment, (b) to obtain amplicon sizes ranging from 299
to 585 bp in length, (c) to allow for a distance of at least
30 bp between the 5-end of a particular primer and the
nearest exon-intron boundary within the amplicon, and
Table 3. PCR Primers and Amplicon Size
Exon Amplicon Primer sequence
Amplicon
size (bp)
GC
%
1 1 F: 5-ACGTTTTCCCCAAGAACCTT-3 R: 5-TTTAACCCTTGGCTTGAAAAA-3 585 38
2* 2 F: 5-GGCTTCCTCTAGCGTTTCCTCCT-3 R: 5-ACGGAAAAGGCAAGTGATGA-3 577 74
3 3 F: 5-TCCGTGGAATATTCACTTCTCC-3 R: 5-AGGGCGAGACTCAGTTTCAA-3 343 33
4 4 F: 5-TTGAATCTGCTTTACTTTCTGCTG-3 R: 5-GCCCCAGAAAACCTCACATA-3 475 36
5 5 F: 5-TGTTGCAAATAGTGGGTTTCC-3 R: 5-CCCACCAAAAGCAGAGAAAA-3 391 30
6 6 F: 5-TTCAGTCACTCTATTCACTCCTCTC-3 R: 5-GAATTTGGGTAAGATGGCTTTT-3 391 39
7 7 F: 5-TTTAATGGCTCATGCTTTTTCA-3 R: 5-TTGTAGGCGAAGAGGGAAAC-3 328 36
8 F: 5-CAGTTTGCACCATTTGTTGG-3 R: 5-GCCCACCCACACTGTTACAC-3 466 41
9 F: 5-ATGAGCGGCCGAATTCTAT-3 R: 5-GCTTTGGGGACAACATTCAT-3 484 44
10 F: 5-CAGTGGGTTCTTTGGCCTTA-3 R: 5-CTGAACAGCAGCATCCACAT-3 449 47
11 F: 5-AGCTGTGACTGGGTCAGGTT-3 R: 5-CCATTGAATTTCACAACAAAGG-3 488 50
8 12 F: 5-TCGGCTTAACTGACTTGAAAA-3 R: 5-GCTTGAGCCATAAGAAATTGTTG-3 299 32
9 13 F: 5-CCTTCCAGTACTGTGTTATTTGTGA-3 R: 5-AAGGACAAACCCTCCAAGTTT-3 459 37
14 F: 5-GATGCCACTTATCCCCAGAA-3 R: 5-TGGGAGTTTGGCAGTATGGT-3 475 37
15 F: 5-CCGATAGCAGTGAGAAAGAGAAA-3 R: 5-GGGTGGGAAATAGGTTCCTT-3 494 36
16 F: 5-TCCAAATGTGCTTGAGTGGT-3 R: 5-ATTGCATGGCCTACATCACA-3 498 40
17 F: 5-GAAAGGCCTCCAAATTATCCA-3 R: 5-CTGGGCAAGTGGACAAAACT-3 384 39
18 F: 5-CCAGCATATTTTGCTTGAGATTT-3 R: 5-TAATGTCACAATAACAGCATTC-3 465 37
19 F: 5-CAGTGAACAAGAAAGCAAACAAA-3 R: 5-TCCCTGGGTCTAGGAGATTC-3 498 38
20 F: 5-TTCTGGAAGAATACCCTTCAGTG-3 R: 5-CTGTTGAGTTCTAAAGGACAGTCG-3 500 36
21 F: 5-CCATTTATAGATGTATTTGGCTGTCA-3 R: 5-GTGGCGACTGTAAATCAGCA-3 484 38
22 F: 5-AGGCTGCTAAGCTCATGAAGA-3 R: 5-TAACAGCAAAGCACCCATTG-3 477 45
23 F: 5-CATGTGGGGCAGTAGGAGTT-3 R: 5-AGGCTGCTGAACCAACATCT-3 492 41
24 F: 5-GCTCATGGAAAAGGGAAAGA-3 R: 5-ACTTTGCAACTCGTCCTTCG-3 466 38
25 F: 5-GGAGTTCTTCGTGTTACTCC-3 R: 5-GTCAGTTGCTGCAAACATGG-3 466 39
26 F: 5-AAGGGATCCTAGAGCAAAGGA-3 R: 5-TGCATTCTCAACTAGAATGAAGC-3 463 37
27 F: 5-CCAGGAGAATATCACCAATGC-3 R: 5-CAAGGGCAATCATTGTAGCA-3 486 35
28 F: 5-TGGAGTCTCATTAGAGAAAAGAAAC-3 R: 5-TTCTGTAAATGGCTGGTTGTTG-3 498 39
29 F: 5-TTCTGTAAATGGCTGGTTGTTGA-3 R: 5-GCGCAGTTTGTCCAAAAGAT-3 496 42
30 F: 5-TGCACAATGTTCAGATTTCCTC-3 R: 5-AATGCAGGCAGCTACTCCAC-3 489 38
31 F: 5-CGTGGCTAATTTGTAATAGATCAGG-3 R: 5-TGCTTTCACTAGACAATATAAATCTGG-3 491 40
32 F: 5-CCCTGGTTCTGATCCAACAT-3 R: 5-TGATATCAGCAGGGGTCACA-3 494 36
33 F: 5-CACGCAAAACAGTAGCAGAGA-3 R: 5-TGGAAATGTCAAACACTTTTGC-3 498 34
34 F: 5-GATGCAAAACGACCCAAGTT-3 R: 5-GCTTTCATTAGAGCATGAAAAAC-3 481 36
35 F: 5-CTGTTTCAGCCAACCAGCTT-3 R: 5-TGTCCATTTCTCCACTTCAGC-3 473 39
36 F: 5-TTGAATCATTTGATGTCCCAAG-3 R: 5-GGAATAAACAATTTTTCAGGAAGC-3 494 34
37 F: 5-CAAGTGCTGAGGAATTATCAGAGA-3 R: 5-GGCCCGCTCAGGACATAA-3 464 33
38 F: 5-TCCTTCTGCATCATATATTCCAA-3 R: 5-CCTCGCAACTGAAAACGAA-3 499 38
39 F: 5-ATGCAACATAACGACGTTGG-3 R: 5-AAGCGCAAGGTCTCGTACAT-3 457 38
40 F: 5-TGAGGGCAAACAATTAGATCC-3 R: 5-TGGCCAGAAAAGCATTATCA-3 497 40
41 F: 5-TTTGTCAGTTTGGAGCGTTG-3 R: 5-TTTTGATGGCTCCGAAGAGT-3 485 36
42 F: 5-GGCAATGACTCTTAAATCAGCA-3 R: 5-GGCTGGTTGGTGTAGAAGGA-3 485 38
43 F: 5-TGCTGACAATTCTAGTTTTCTAGG-3 R: 5-GAGGCCCTGTCTGCATTTT-3 486 40
44 F: 5-TGAAATGGCATCCTGACAAA-3 R: 5-TCAGACTTTCCCCTCACAGC-3 490 42
45 F: 5-CACGCAGATGGCTAAGACAA-3 R: 5-TGGCAATGAAGCTTAATGAAGTA-3 483 39
*Amplicon that has not been validated.
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(d) to have at least 100 bp overlapping sequence for
neighboring amplicons of the same exon. An overlap will
ensure the identification of a heterozygous deletion en-
compassing a single or multiple amplicons that could
otherwise escape detection. Furthermore a minimum of
30 bp between the beginning of a primer and an exon-
intron boundary are present in each amplicon, where
applicable. To enable a rapid confirmation by automated
sequencing of sequence variants identified by CSCE, the
amplicons to be analyzed by CSCE were identical to the
amplicons to be analyzed by sequencing. This approach
also reduces the consumable costs, since identical
primer pairs for both CSCE as well as sequencing can be
used. This method is feasible, since there is no need to
split amplicons into smaller fragments to comply with the
presence of multiple melting domains, like in denaturing
gradient gel electrophoresis- or denaturing high perfor-
mance liquid chromatography-based approaches.
To automatically analyze the CSCE electropherograms
of the different amplicons of the SACS gene by the data
analysis software program Bionumerics an optimized set
of parameters (quantified characteristics of the shapes of
the electropherogram) has been used that was devel-
oped during a separate technical validation of CSCE.
Essentially, the position and shape of the peak of a nor-
mal (no DNA variant-containing) reference electrophero-
gram is compared with the peak positions and shapes of
the electropherogram to be analyzed. The parameters
used are described in the Materials and Methods.
Validation
A generic technical validation of the experimental con-
ditions of CSCE and the optimal general settings of the
software program BioNumerics has been performed
previously. In this collaborative study (Interlaboratory
Diagnostic Validation of Confirmation Sensitive Capillary
Electrophoresis, to be published in detail elsewhere) pa-
rameters including (1) CG-content of fragments, (2) po-
sition of the DNA-variant relative to the primers, (3) frag-
ment length, and (4) temperature during electrophoresis
have been analyzed. The main results are that (1) CG-
content of 30% to 60% gives optimal results, whereas for
amplicons with a CG-content up to 80% different condi-
tions may be necessary (2), SNPs close to a primer may
escape detection, an issue that can be circumvented by
the design of the analytical strategy, eg, by taking suffi-
cient overlap of amplicons into account, (3) length of
amplicons up to 500 bp can still be analyzed reliably, and
(4) cooling of the oven temperature below 15°C, which
improves separation of heteroduplex bands.6
As a result of the design and analytical validation of the
CSCE system for mutation scanning of the SACS gene
presented in this paper, the five pattern matching param-
eters were set at specific lower and upper threshold
values (Table 4). Patterns with parameter values above
one or more of these thresholds are considered to be
divergent (indicated by red) and patterns with one or
more parameter values below a certain threshold are
considered to be normal (indicated by green). Patterns
with one or more parameter values between these two
thresholds are slightly divergent (indicated by orange).
These patterns always need to be visually inspected.
For analytical validation of the use of CSCE to the
detection of DNA variants specifically in the SACS gene
in total 52 DNA samples containing a total of 51 different
variants occurring in 32 different amplicons of the SACS
gene have been analyzed. The PCR products ranged in
length from 299 to 585 bp. The validation process con-
sisted of a retrospective phase and a prospective phase.
In the first phase, 32 DNA samples of index patients with
known variants, previously identified by sequencing of
the SACS gene were used retrospectively to determine
the analytical sensitivity of the CSCE approach. In the
second phase, to further assess the analytical sensitivity
and to determine the analytical specificity, we performed
CSCE and subsequent sequencing of the SACS gene
prospectively in a cohort of 20 DNA samples from pa-
tients for whom mutation analysis of the SACS gene was
requested for clinical purposes.
Phase One (Retrospective Analysis)
To test the analytical sensitivity of the CSCE 32, DNA
samples containing 41 different known variants were ret-
rospectively used. These 41 known variants occur in 25
different amplicons (4/29 amplicons are redundant due to
overlaps with flanking amplicons) of the SACS gene. Of
these 41 variants 24 are nonpathogenic SNPs (Table 2)
and 17 of these are pathogenic mutations (Table 1).
Fourteen out of these 17 have recently been described as
a novel pathogenic mutation.7 Two DNA samples, with
three different known mutations in the SACS gene, were
kindly made available by Dr. F.M. Santorelli from Italy.5
Samples carrying a homozygous variation were mixed
with a mutation-negative reference sample. All 41 varia-
tions could be detected by CSCE, except for two SNPs in
amplicons 3 and 11, respectively. The first SNP c.172-
129AG, which is located just one bp next to the forward
primer of amplicon 3 (exon 3), displayed a completely
normal pattern and could not be distinguished from the
reference pattern (Figure 1). All pattern parameters had
values below the initial threshold settings (Table 4). The
pattern of the second SNP c.2080GA at position 151 of
the 488 bp long amplicon 11 (exon 7) did not show a
clear heteroduplex band. The pattern differed just slightly
Table 4. Peak Matching Parameters
Parameter
Threshold
Green (II) Green (I) Orange Red
SRMS 3.50 7.00 7 20.00
MAX 3.50 6.00 7 20.00
SECPK 200.00 200.00 7 400.00
DFH3 1.00 1.00 7 1.70
DFH4 0.70 0.70 7 1.20
The parameters and settings are described in the Materials and
Methods. Peaks indicated in green should be considered as normal
and do not require subsequent sequencing. Green II indicates the
adapted parameters. Peaks indicated in orange need further visual
inspection and peaks indicated in red always require sequencing.
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from the reference peak. All pattern parameter values
were below the initial threshold settings, except for the
MAX value (6.1%), which was just above the threshold.
The CG-content of this amplicon was 50%, which is the
highest of all (mean, 39%). All other variants could clearly
be detected regardless of their position in the amplicon
or the CG-content of the amplicon. On duplication, iden-
tical results were obtained.
Phase Two (Prospective Analysis)
To further assess the analytical sensitivity and to deter-
mine the analytical specificity of CSCE for the SACS
gene, CSCE and sequencing was performed in parallel
for all 44 amplicons (except amplicon 2) of the SACS
gene in a cohort of 20 individuals for whom mutation
analysis of the SACS gene was requested for clinical
purposes. In this cohort an additional 10 novel variants,
including two pathogenic mutations (c.9911_9912del/
p.Leu3304fs and c.10442TC/p.Leu3481Pro) were de-
tected. Four of these additional variants occurred in three
additional amplicons that could not be assessed in the
first phase, since no samples containing variants in these
amplicons were available at that stage. All 73 variants
present in this cohort, including eleven known variants,
occurring in 18 different amplicons (including two over-
lapping amplicons) could be detected by CSCE, except
again for the SNP in fragment 11 (exon 7), which gave a
false negative score. This results in an analytical sensi-
tivity of 98.6% before further optimization of the design,
and of 100% after optimization. This optimization includes
an optimized primer design for amplicon 3, resulting in
successful detection of SNP c.172-129AG, and of re-
laxation of parameter settings of the data analysis pro-
gram (Table 4 II), resulting in the successful detection of
SNP c.2080GA in amplicon 11 (exon 7).
Two true false-positive results were observed in two
different amplicons 38 (exon 9) (Figure 2) and 39 (exon 9)
respectively, giving a false-positive variant detection rate
of 0.25% with an analytical specificity of 99.8%.
As all samples are mixed with PCR product of a refer-
ence sample negative for pathogenic SACS mutations, it
cannot be determined from the raw data whether a DNA
variant that has been detected is homozygous or het-
erozygous in the test sample. Out of 73 alterations de-
tected, nine turned out to be homozygous variations after
sequencing.
Due to overlap in the amplicons, five variations have
been detected in two consecutive amplicons (Tables 1
and 2; one example is shown in Figure 3). In three sam-
ples, two variations per amplicon (15, 35, and 41 [exon9])
were present, resulting in a pattern of multiple conforma-
tional changes (cf. example in Figure 4A and B). The
separate patterns when occurring as a single variation
are displayed beneath for comparison.
Figure 1. Example of initially false negative capillary heteroduplex electro-
pherogram. This electropherogram shows the analysis of amplicon 11 con-
taining the heterozygous SACS c.2080GA variation, indicated by the arrow.
The pattern of the sample containing the variation and the pattern of the
normal genotype sample are virtually identical. This variation is located at
nucleotide 151 of the 488 nucleotides in total. This variation could be
detected after optimization of the threshold values of the data analysis
software (Bionumerics). This underlines that optimization of the data analysis
program is crucial.
Figure 2. Example of false positive capillary heteroduplex electrophero-
gram. This electropherogram shows the true false-positive result in amplicon
38 (exon 9).
Figure 3. Example of a variation in two overlapping fragments. Due to
overlap in the amplicons, five variations have been detected in two consec-
utive amplicons (Tables 2 and 3). Figure 3 shows the mutation (indicated by
the arrow) c.1475GA in amplicon 9 (located at nucleotide 448 of the 484
nucleotides in total) and 10 (at nucleotide 84 of the 449 in total).
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Discussion
DNA diagnostic service laboratories are receiving a
steadily increasing number of requests for confirmation
or exclusion of the clinical diagnosis of a particular ge-
netic disease by DNA techniques. This requires efficient
mutation scanning of disease-causing genes by tech-
niques such as automated sequencing, denaturing high
performance liquid chromatography, denaturing gradient
gel electrophoresis, melting curve analysis, or CSCE. For
very large genes, such as the SACS gene, mutation
scanning is labor intensive and costly with regards to
consumable use. Therefore it is desirable to develop
alternative scanning methods that are reliable, rapid and
inexpensive. CSCE is such a method, and here we de-
scribe in detail the design and analytical validation of
CSCE for the SACS gene, including the pitfalls and diffi-
culties encountered.
Development and Design
To design and test the use of CSCE as a fully automated
scanning method for the large SACS gene, 52 DNA sam-
ples were used for development of optimal running con-
ditions for the different amplicons, for development of
optimal automated data analysis parameters, and for
subsequent analytical validation. A first important conclu-
sion we can draw from the process of developing a CSCE
system is that the developmental and validation stages of
the process have to be performed consecutively in
clearly distinct phases. The distinction has to be made to
prevent that adaptations made to the CSCE system or the
analysis software criteria that may be necessary to make
to comply with the performance criteria, result in a dis-
turbed validation process. This requires the definition of
clear and unambiguous performance criteria for the
CSCE system and the automated data analysis software
before the development process has started. These a
priori performance criteria are a high analytical sensitivity
of at least 99% and an analytical specificity of at least
96% for the CSCE system. In addition, the robustness of
the technique has to be very good (less than 5% failure
rate) and the costs compared with automated sequenc-
ing of the complete coding region of the gene under
study should be less than 50%.
To detect a homozygous mutation by CSCE in an
autosomal recessive condition such as ARSACS, DNA of
the parents could in principle be used for analysis. How-
ever, since DNA of parents is not always available we
have chosen to mix PCR product of a patient (test-DNA)
with PCR product of a mutation-negative reference sam-
ple (reference-DNA). In this procedure, it is very impor-
tant to monitor the amount of the PCR product of interest
on an agarose gel before CSCE analysis by estimating
the ethidium bromide staining intensity to avoid aberrant
results, eg, by erroneously analyzing just reference-DNA,
or reversely unmixed test-DNA.
For amplicon 2 (exon 2) a different PCR mix and PCR
program is used because of its high CG-content (75%).
With CSCE no reliable results could be obtained for this
amplicon, and therefore this amplicon is excluded from
the CSCE analytical strategy, and directly sequenced. It
has been documented previously that a very high or a
very low CG-content reduces the sensitivity of heterodu-
plex methods.8
After identifying the false-negative SNP c.2080GA in
amplicon 11 (exon 5) the lower limits of the peak match-
ing parameters were changed into more relaxed param-
eters (Table 4). With these newly lower limit parameters
the false-negative SNP in amplicon 11 could easily be
detected. The other false negative SNP c.172-129AG in
amplicon 3 (exon 3) underlines the importance of design-
ing primers not to close to the intron-exon boundary, as a
variant that is located close to, and in this instructive
example only one bp apart from the primer, will not be
detected by CSCE. In our cohort the position of the
variants detected ranged from 1 bp distance to the
forward primer to 10 bp distance to the reverse primer. In
conclusion, after adaptation of the parameters of the data
analysis program, and redesign of the amplicons also
these two false-negative SNPs could be detected by
CSCE. This results in an overall final analytical sensitivity
of 100%.
Four primers (18RP, 19FP, 20FP, 20RP) had to be rede-
signed, due to four different variants that occurred under-
neath the primers. Two of these are pathogenic mutations
(c.4108CT/p.Gln1370X and c.4957GT/p.Glu1653X) and
the other two are SNPs (c.4188CT, c.4466AG). These
redesigned primers have also been tested and validated,
and showed normal results.
Figure 4. Example of two variations in a single amplicon. In three samples,
two variations per amplicon (15, 35, and 41 [exon 9]) were present, resulting
in a pattern of multiple conformational changes. For example, panel A
(amplicon 41 [c.12160CT and c.12304TC]) shows multiple conformational
changes as the variants are located on different alleles. The separate patterns
when occurring as a single variation (B) are displayed beneath for compar-
ison. The arrows indicate the variations.
Mutation Scanning SACS Gene by CSCE 521
JMD November 2009, Vol. 11, No. 6
In Figure 4, the capacity of the CSCE technique to
detect multiple variants located on different alleles in a
single amplicon is shown. This could be used to design
a strategy to discriminate a mutation from known SNPs
with relatively high occurrence in the population by
admixture of a reference fragment containing the par-
ticular SNP with the corresponding fragment of a pa-
tient before heteroduplex formation. This strategy
could be extended to all amplicons containing known
frequently occurring SNPs. By this strategy the number of
additionally required subsequent sequencing reactions
can be reduced.
Validation
The use of CSCE as a fully automated mutation scanning
method for the large SACS gene has been validated. A
recurrent issue in the discussion on how to perform a
reliable validation of a DNA-variant (mutation) scanning
technique is whether it is necessary to verify the capacity
to identify the presence of a DNA-variant in each ampli-
con of the scanning system. For a rare disease such as
ARSACS, not in all amplicons of the SACS gene a DNA-
variant is known. Furthermore, it is virtually impossible to
obtain samples containing known variants from other lab-
oratories on request. To get an impression on the re-
sponse rate, requests for samples containing known DNA
variants from patients known from literature were sent out
to six different laboratories, to be able to test the detec-
tion capacity of an additional six amplicons. From just
one laboratory (Dr. F.M. Santorelli) two samples contain-
ing three mutations in three different amplicons were
obtained. Therefore 12 of the 44 amplicons could not be
directly tested for their capacity to detect a DNA variant in
our validation process. Since in the technical validation of
CSCE performed in collaboration with the groups of Mat-
thijs (Leuven, Belgium), Mattocks (Salisbury, UK) and
Applied Biosystems (Interlaboratory Diagnostic Valida-
tion of Confirmation Sensitive Capillary Electrophoresis),
to be published in detail elsewhere, it could be shown
that all DNA variants could be detected by CSCE when
taking a number of running conditions into account. We
concluded that an analytical validation of the CSCE tech-
nique for the application of the SACS mutation scanning
would suffice when using identical running conditions,
and that the analysis of eg, PCR products with artificially
created SNPs for amplicons for which no known SNPs
were available would be superfluous.6 These running
conditions and the recipe of the conformation analysis
polymer used have been summarized in Table 5 and 6,
respectively. We could conclude that an oven tempera-
ture of 12°C results in an optimal separation of heterodu-
plex bands here fore a specific adjustment to the ABI
3730 automated sequencer had to be made to set this
oven temperature (Table 6).
To assess the analytical sensitivity and the analytical
specificity of CSCE for the SACS gene, we compared it to
DNA sequencing. In the analytical validation 32 of the 44
amplicons of the SACS gene could be assessed directly.
Initially, two SNPs could not be detected. After further
optimization, an overall analytical sensitivity of 100% was
determined since all 114 DNA variants identified by DNA
sequencing could also be identified by CSCE. The overall
analytical specificity was 99.8% as a result of two false-
positive results. Settings described in this study demon-
strate the experimental conditions resulting in an optimal
balance between sensitivity and specificity. However, to
be safer with regard to the analytical sensitivity and thus
taking less risk in obtaining false negative results, the
stringency of the settings could be relaxed, accepting the
possibility of a slightly lower specificity.
Mismatches in heteroduplex molecules can be de-
tected best in smaller fragments. We have observed that
to achieve optimal sensitivity amplicons should have a
maximum length of 500 bp.6 However in this study we
noticed that amplicons even longer than 500 bp can
easily be analyzed by CSCE.
Robustness
Initially, capillary overloading resulting in high peaks that
cannot be interpreted by the analysis software was ob-
served in a number of samples. This indicates that the
DNA concentration of the samples needs to be monitored
in process, and will be better controllable by automation
of liquid handling during the amplification and sequenc-
ing steps. Introduction of DNA concentration monitoring
and automated liquid handling resulted in a reduction of
the failure rate to below 5%.
Table 5. Running Conditions CSCE
Run condition Value Range
Oven temperature 12°C 12–70
Buffer temperature 35°C 30–35
Pre-run voltage 15 kV 0–15
Injection time 20 seconds 1–90
Pre-run time 180 seconds 1–1800
Injection voltage 3 kV 0–15
First read out time 180 ms 100–16,000
Exposure time 0 ms 0–5000
Run voltage 13 kV 15
Voltage number of steps 10 kV 0–100
Voltage step interval 20 seconds 0–180
Voltage tolerance 0.6 kV 0–6
Current stability 500 mA 0–2000
Ramp delay 200 seconds 1–800
Data delay 750 seconds 1–1800
Run time 5200 seconds 300–14.000
Buffer to run consists of 1 TTE, 10% glycerol (national diagnostic,
EC-871).
Table 6. Recipe CAP
CAP (Applied Biosystems, 434037) 12.67 g
Ureum (1 kg, pro analyse, Merck) 5.27 g
Sucrose (250 g, for biochem, Merck) 2.03 g
20 TTE (national diagnostic, EC-871) 1.14 g
MQ 1.72 g
After a generic technical intern validation of the experimental
conditions of CSCE an oven temperature of 12°C resulted in optimal
separation of heteroduplex bands. A specific adjustment to the ABI
3730 automated sequencer had to be made to set this oven
temperature.
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To improve in process quality control the use of a Liz
500 size standard containing a DNA fragment in which a
heterozygous DNA variant has been created has been
introduced, which allows monitoring of the capillary sep-
aration capacity of the conformation analysis polymer.
Costs
To improve cost-effectiveness CSCE with two differently
labeled primers (5-carboxyfluorescein and VIC) can be
considered. However, in our experience the use of a
single labeled primer (5-carboxyfluorescein) is prefera-
ble, due to translucency and interference between the
differently labeled peaks. Furthermore, to avoid substan-
tial differences in signal intensity between the differently
labeled peaks, an additional effort in optimization would
be required.
Roughly CSCE is, by a factor of six, cheaper than
sequencing. As only those amplicons that show a diver-
gent CSCE pattern need to be sequenced, instead of the
entire coding sequence of the gene, a substantial cost
reduction is achieved. If two differently labeled primers
would be used the difference in costs compared with
automated sequencing would even be a factor of 12.
Since one of the mutations (c.12160CT/p.Gln4054X)
has a high relative frequency in ARSACS patients of
Dutch descent (identified either homozygously or het-
erozygously in seven of the so far 16 families identified)
we are considering to perform a pre-screening by direct
sequencing of this amplicon (41, exon 9). For reasons of
efficiency, this will then be combined with the sequencing
of amplicon 35 (exon 9) containing two common SNPs,
with a high relative frequency, eg, for one of these SNPs
(c.9981CT) both reference samples V3 and V4 are
heterozygous.
Mutation Spectrum
So far we have performed mutation analysis of the SACS
gene in 76 index patients. In total, 16 novel pathogenic
mutations were identified in 16 different families consist-
ing of 23 patients. In the remaining 60 index patients no
mutations were identified, which most likely reflects the
fact that they have a different genetic condition. Most
mutations (13) identified are truncating mutations, and
three are missense mutations. Furthermore 36 different
SNPs were identified of which one is a very common SNP
(c.9981CT) with an estimated minor allele frequency of
0.37. Large deletions of the SACS gene as identified in a
Belgian ARSACS patient4 will be missed by both CSCE
and sequencing. Therefore in the near future an MLPA-
test for the SACS gene will be set up.
Conclusion
Based on the various locations of the 52 variations in 32
different amplicons with different fragment lengths, and
different CG-content our results show a high sensitivity (
100%) and specificity (99.8%) for the use of CSCE as a
mutation scanning method for DNA variant identification
of the SACS gene.
Our recommendation would be to perform sequence
analysis of all amplicons with divergent peaks (orange or
red) after CSCE and to perform direct sequence analysis
of all amplicons with common SNPs with a high minor
allele frequency (eg, over 0.25) in the population.
We can conclude that CSCE is a robust technique with
a high sensitivity and specificity, and is highly suitable for
application in mutation scanning for large genes such as
the SACS gene.
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